[1] |
杨丽萍, 梁勤, 杨建忠, 等. 三种血清标志物联合检测对肝细胞肝癌的诊断价值研究[J]. 甘肃医药, 2023, 42:289-292.
|
[2] |
Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21:8165-8184.
|
[3] |
Xue M, Wu Y, Fan W, et al. Prognostic value of TP53 mutation for transcatheter arterial chemoembolization failure/refractoriness in HBV-related advanced hepatocellular carcinoma[J]. Cancer Res Treat, 2020, 52:925-937.
|
[4] |
Sun L, Zhou X, Li Y, et al. KLF5 regulates epithelial-mesenchymal transition of liver cancer cells in the context of p53 loss through miR-192 targeting of ZEB2[J]. Cell Adh Migr, 2020, 14:182-194.
|
[5] |
刘贵珍, 杨瑞红, 李宝连. 血清lncRNA DLX6-AS1 Actinin-4表达与宫颈癌术后复发及预后的关系[J]. 河北医学, 2022, 28:1689-1696.
|
[6] |
Wang G, Li Y, Tang B, et al. Alpha-actinin 4 and tumorigenesis of hepatocellular carcinoma[J]. Transl Cancer Res, 2019, 8:1374-1380.
|
[7] |
中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作委员会, 中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治专家共识[J]. 临床肿瘤学杂志, 2009, 14:259-269.
|
[8] |
孟聪聪, 张艳凯, 于利利, 等. 甲状腺乳头癌组织中KLF5、TAZ、UHRF1的表达水平及其临床意义[J]. 实用癌症杂志, 2023, 38:771-774.
|
[9] |
Liu P, Wang Z, Ou X, et al. The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition[J]. Mol Cancer, 2022, 21:198-216.
|
[10] |
Zhang B, Li Y, Wu Q, et al. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer[J]. Nat Commun, 2021, 12:1714-1734.
|
[11] |
Gao W, Lu YX, Wang F, et al. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5[J]. Eur Rev Med Pharmacol Sci, 2019, 23:7874-7883.
|
[12] |
Wang J, Chu Y, Xu M, et al. miR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5[J]. Oncol Lett, 2019, 17:2221-2227.
|